Abivax achieves key milestone in phase 3 abtect trial enrollment

Abivax achieves key milestone in phase 3 abtect trial enrollment phase 3 abtect trial evaluating obefazimod for moderately to severely active ulcerative colitis (“uc”) reaches 1,003 of 1,224 participants, representing 82% of target enrollment. enrollment completion expected in q2 2025.
ABVX Ratings Summary
ABVX Quant Ranking